

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Steven M. Watkins

Application No. _____

Filed: Herewith

Confirmation No. _____

For: GENERATING, VIEWING, INTERPRETING,
AND UTILIZING A QUANTITATIVE
DATABASE OF METABOLITES

Examiner: Not yet assigned.

Art Unit: Not yet assigned.

Attorney Reference No. 6556-67579

MAIL STOP PATENT APPLICATION
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(b)(1)

Listed on the accompanying form PTO-1449 and enclosed herewith are several English-language documents. Applicant respectfully requests that these documents be listed as references cited on the issued patent.

Applicant are filing this Information Disclosure Statement ("IDS") within three months of the filing date of a national application. As a result, no fee should be required to file this IDS. If the Commissioner determines that a fee is due, Deposit Account Authority is provided on the accompanying transmittal letter. The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.

Respectfully submitted,
KLARQUIST SPARKMAN, LLP

By _____
Tanya M. Harding, Ph.D.
Registration No. 42,630

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446

INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Attorney Docket Number	6556-67579
	Application Number	
	Filing Date	Herewith
	First Named Inventor	Watkins
	Art Unit	Not yet assigned.
	Examiner Name	Not yet assigned.

U.S. PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Name
		3,847,550	11/12/1974	Scott <i>et al.</i>
		5,075,101	12/24/1991	Siguel
		5,773,300	06/30/1998	Federighi <i>et al.</i>
		6,185,561	02/06/2001	Balaban <i>et al.</i>
		6,188,783	02/13/2001	Balaban <i>et al.</i>
		6,223,127	04/24/2001	Berno
		6,229,911	05/08/2001	Balaban <i>et al.</i>
		6,308,170	10/23/2001	Balaban
		6,576,471	06/10/2003	Otvos

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Number	Date	Country
		WO 99/05574	04 Feb. 1999	PCT
		WO 99/05591	04 Feb 1999	PCT
		WO 99/32660	01 July 1999	PCT
		WO 01/04622	18 Jan. 2001	PCT
		WO 01/20043	22 Mar. 2001	PCT
		WO 01/23614	05 Apr. 2001	PCT

EXAMINER
SIGNATURE:

DATE
CONSIDERED:

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	6556-67579
		Application Number	
		Filing Date	Herewith
		First Named Inventor	Watkins
		Art Unit	Not yet assigned.
		Examiner Name	Not yet assigned.
Examiner's Initials*	Cite No. (optional)	OTHER DOCUMENTS	
		Boersma <i>et al.</i> , "19F NMR metabolomics for the elucidation of microbial degradation pathways of fluorophenols," <i>Ind. Microbial Biotechnol.</i> , 26(1/2):22-34, January 2001 (Abstract only)	
		Fiehn, "Combining genomics, metabolome analysis, and biochemical modelling to understand metabolic networks," <i>Comp. Funct. Genom.</i> , 2:155-168, 2001	
		Griffin <i>et al.</i> , "Metabolic Profiling of Genetic Disorders: A multitissue (1)H Nuclear Magnetic Resonance Spectroscopic and Pattern Recognition Study into Dystrophic Tissue," <i>Anal. Biochem.</i> , 293(1):16-21, June 1, 2001 (Abstract only)	
		Jardine and Holdaas, "Fluvastatin in combination with cyclosporin in renal transplant recipients: A review of clinical and safety experience," <i>J. Clinical Pharmacy and Therapeutics</i> , 24(6):397-408, December 1999 (Abstract only)	
		Lithell, "Hypertension and hyperlipidemia: A review," <i>Am. J. of Hypertension</i> , 6(11):303S-308S, 1993 (Abstract only)	
		Raamsdonk <i>et al.</i> , "A functional genomics strategy that uses metabolome data to reveal the phenotype of silent mutations," <i>Nature Biotechnology</i> , 19:45-50, January 2001	
		Saudek and Eder, "Lipid Metabolism in Diabetes Mellitus," <i>Am. J. Med.</i> , 66(5):843-852, 1979 (Abstract only)	
		Siguel <i>et al.</i> , "Criteria for essential fatty acid deficiency in plasma as assessed by capillary column gasliquid chromatography," <i>Clin. Chem.</i> , 33(10):1869-1873, October 1987 (Abstract only)	
		Siguel, "Diagnosing Essential Fatty Acid Deficiency," <i>Circulation</i> , 97(25):2580-2583	
		Siguel <i>et al.</i> , "Monitoring the optimal infusion of intravenous lipids. Detection of essential fatty acid deficiency," <i>Arch. Pathol. Lab. Med.</i> , 110(9):792-797, September 1986 (Abstract only)	
		Siguel and Maclure, "Relative activity of unsaturated fatty acid metabolic pathways in humans," <i>Metabolism</i> , 36(7):664-9, July 1987 (Abstract only)	
		Tanaka and Hine, "Compilation of gas chromatographic retention indices of 163 metabolically important organic acids and their use in detection of patients with organic acidurias," <i>J. Chromatogr.</i> 239:301-322, April 30, 1982 (Abstract only)	
		Tate <i>et al.</i> , "Lipid metabolite peaks in pattern recognition analysis of tumour in vivo MR spectra," <i>Anticancer Res.</i> , 16(3B):1575-1579, May-Jun, 1996 (Abstract only)	

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Attorney Docket Number	6556-67579
		Application Number	
		Filing Date	Herewith
		First Named Inventor	Watkins
		Art Unit	Not yet assigned.
		Examiner Name	Not yet assigned.
		Trethewey, "Gene discovery via metabolic profiling," <i>Curr. Opin. Biotechnol.</i> , 12(2):135-138, April 2001 (Abstract only)	
		Tweeddale <i>et al.</i> , "Effect of slow growth of metabolism of <i>Escherichia coli</i> , as revealed by global metabolite pool ("metabolome") analysis," <i>J. Bacteriol.</i> , 180(19):5109-5116, October 1998 (Abstract only)	
		Vigneau-Callahan <i>et al.</i> , "Characterization of diet-dependent metabolic serotypes: analytical and biological variability issues in rats," <i>J. Nutr.</i> , 131(3):924S-932S, March 2001 (Abstract only)	
		Waters <i>et al.</i> , "NMR and pattern recognition studies on liver extracts and intact livers from rats treated with alpha-naphthylisothiocyanate," <i>Biochem. Pharm.</i> , 64(1):67-77, July 1, 2002 (Abstract only)	
		Watkins, "Comprehensive Lipid Analysis: A Powerful Metanomic Tool for Predictive and Diagnostic Medicine," <i>IMAJ</i> , 2:722-724, September 2000	
		Watkins <i>et al.</i> , "Individual metabolism should guide agriculture toward foods for improved health and nutrition," <i>Am. J. Clin. Nutr.</i> , 74:283-286, 2001	
		"Functional Genomics in Aberystwyth," http://gepasi.dbs.aber.ac.uk/dbk/fungen.htm , (1 page) printed 06/16/2001	
		Hofestädt and Thelen, "Quantitative Modeling of Biochemical Networks," http://www.bioinfo.de/isb/1998/01/0006/main.html , (12 pages), printed 05/20/2002	
		Siguel, "A New Relationship Between Polyunsaturated Fatty Acids and Total/HDL Cholesterol," <i>Lipids</i> , 31:S51-S56, 1996, http://www.efafod.com/tchdlc.htm , (6 pages) printed 06/09/2001	
		Siguel, "How to evaluate a laboratory that performs fatty acid analysis," http://www.efafod.com/goodlab.htm , (8 pages) printed 06/09/2001	
		Siguel, "High total calories and low EFAs are more likely than fat to be the major culprit in heart disease and cancer," http://www.efafod.com/lowfat.htm , (6 pages), printed 06/09/2001	

EXAMINER SIGNATURE:	DATE CONSIDERED:
* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.	